share_log

Cybin | SC 13G: Statement of acquisition of beneficial ownership by individuals-Deep Track Capital, LP(7.65%),Deep Track Biotechnology Master Fund, Ltd.(7.65%), etc.

Cybin | SC 13G: Statement of acquisition of beneficial ownership by individuals-Deep Track Capital, LP(7.65%),Deep Track Biotechnology Master Fund, Ltd.(7.65%), etc.

Cybin | SC 13G：超過5%持股股東披露文件-Deep Track Capital, LP(7.65%),Deep Track Biotechnology Master Fund, Ltd.(7.65%)等
SEC announcement ·  03/22 16:08
Moomoo AI 已提取核心訊息
On March 14, 2024, a Schedule 13G filing was made with the United States Securities and Exchange Commission by Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., and David Kroin, indicating a significant ownership stake in Cybin Inc. The filing revealed that the reporting entities collectively hold 58,139,535 common shares of Cybin Inc., representing 7.65% of the company's class of securities. The shares are held with shared voting and dispositive power. The filing, made under Rule 13d-1(c), is not intended to effect a change in control of Cybin Inc. but is a standard disclosure for entities owning more than five percent of a class of a company's shares. The principal business office addresses for the reporting persons are located in Greenwich, CT, and George Town, Cayman Islands, with citizenships in Delaware, Cayman Islands, and the United States, respectively. The filing was certified by David Kroin, the Managing Member of the General Partner of the Investment Adviser for Deep Track Capital, LP, and Director of Deep Track Biotechnology Master Fund, Ltd.
On March 14, 2024, a Schedule 13G filing was made with the United States Securities and Exchange Commission by Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., and David Kroin, indicating a significant ownership stake in Cybin Inc. The filing revealed that the reporting entities collectively hold 58,139,535 common shares of Cybin Inc., representing 7.65% of the company's class of securities. The shares are held with shared voting and dispositive power. The filing, made under Rule 13d-1(c), is not intended to effect a change in control of Cybin Inc. but is a standard disclosure for entities owning more than five percent of a class of a company's shares. The principal business office addresses for the reporting persons are located in Greenwich, CT, and George Town, Cayman Islands, with citizenships in Delaware, Cayman Islands, and the United States, respectively. The filing was certified by David Kroin, the Managing Member of the General Partner of the Investment Adviser for Deep Track Capital, LP, and Director of Deep Track Biotechnology Master Fund, Ltd.
2024年3月14日，Deep Track Capital, LP、Deep Track Biotechnology Master Fund, L.和David Kroin向美國證券交易委員會提交了附表13G的文件，表明Cybin Inc.擁有大量所有權。該文件顯示，申報實體共持有Cybin Inc.的58,139,535股普通股，佔該公司證券類別的7.65％。這些股份以共同的投票權和處置權持有。該文件是根據第13d-1（c）條提交的，無意變更對Cybin Inc.的控制權，而是對擁有某類公司股份超過5％的實體的標準披露。申報人的主要辦公地址位於康涅狄格州格林威治和開曼群島喬治城，國籍分別位於特拉華州、開曼群島和美國。該文件由Deep Track Capital, LP投資顧問普通合夥人管理成員兼Deep Track Biotechnology Master Fund, Ltd董事大衛·克羅因認證。
2024年3月14日，Deep Track Capital, LP、Deep Track Biotechnology Master Fund, L.和David Kroin向美國證券交易委員會提交了附表13G的文件，表明Cybin Inc.擁有大量所有權。該文件顯示，申報實體共持有Cybin Inc.的58,139,535股普通股，佔該公司證券類別的7.65％。這些股份以共同的投票權和處置權持有。該文件是根據第13d-1（c）條提交的，無意變更對Cybin Inc.的控制權，而是對擁有某類公司股份超過5％的實體的標準披露。申報人的主要辦公地址位於康涅狄格州格林威治和開曼群島喬治城，國籍分別位於特拉華州、開曼群島和美國。該文件由Deep Track Capital, LP投資顧問普通合夥人管理成員兼Deep Track Biotechnology Master Fund, Ltd董事大衛·克羅因認證。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息